CHD2 NMD Exon Targeting in Patient and CRISPR-generated Cell Lines.

Project: Research project

Project Details


CHD2 NMD exon targeting in patient and CRISPR generated cell lines. The initial proof of principle experiments is to establish whether targeting an NMD-inducing exon can restore CHD2 protein expression in haploinsufficient lines to levels similar to those in control individuals.
Effective start/end date9/5/199/5/20


  • Stoke Therapeutics, Inc. (Agmt 9/5/19)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.